Program
pimasertib
Also written as “Pimasertib”, “MSC1936369B” and “Pimasertib Capsule (Part A)”.
Its studies are mostly in Neoplasms · Melanoma · Neoplasm Metastasis · Ovarian Neoplasms · Carcinoma, Hepatocellular, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Merck KGaA, Darmstadt, Germany | 110 open or running | phase 2since Aug 11, 2009 | Aug 11, 2009 | none ahead |
| Day One Biopharmaceuticals | 10 open or running | phase 1since Jul 3, 2025 | Jul 3, 2025 | none ahead |
| Sanofi | 10 open or running | phase 1since May 16, 2011 | May 16, 2011 | none ahead |
Also a collaborator on its studies: merck-serono-s-a-geneva and merck-serono-co-ltd-japan.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 11, 2009First study: phase 2 study in Leukemia, Myeloid, AcuteNew to Merck KGaA, Darmstadt, GermanyMerck KGaA, Darmstadt, Germany · NCT00957580 · 81 enrolled · United States, France
- Sep 22, 2009Phase 1 study in NeoplasmsMerck KGaA, Darmstadt, Germany · NCT00982865 · 182 enrolled · Australia, Belgium, France and more
- Nov 18, 2009Phase 2 study in NeoplasmsMerck KGaA, Darmstadt, Germany · NCT01016483 · 141 enrolled · United States, Germany
- Mar 4, 2010Phase 2 study in Colorectal NeoplasmsMerck KGaA, Darmstadt, Germany · NCT01085331 · 16 enrolled · Belgium, Italy, Spain
- Apr 18, 2011Phase 1 study in Neoplasm MetastasisMerck KGaA, Darmstadt, Germany · NCT01390818 · 146 enrolled · United States, Italy, Spain
- May 16, 2011Sanofi's first study: phase 1 study in Neoplasm MetastasisNew to SanofiSanofi · NCT01357330 · 18 enrolled · United States
- Jun 20, 2011Phase 1 study in NeoplasmsMerck KGaA, Darmstadt, Germany · NCT01378377 · 33 enrolled · United States
- Aug 15, 2012Phase 1 study in Carcinoma, HepatocellularMerck KGaA, Darmstadt, Germany · NCT01668017 · 26 enrolled · Japan
- Sep 13, 2012Phase 1 study in NeoplasmsMerck KGaA, Darmstadt, Germany · NCT01713036 · 6 enrolled · Hungary
- Sep 14, 2012Phase 2 study in MelanomaMerck KGaA, Darmstadt, Germany · NCT01693068 · 194 enrolled · United States, Australia, Belgium and more
- Aug 23, 2013Phase 2 study in Ovarian NeoplasmsMerck KGaA, Darmstadt, Germany · NCT01936363 · 65 enrolled · United States, Australia, Belgium and more
- Nov 8, 2013Phase 1 study in NeoplasmsMerck KGaA, Darmstadt, Germany · NCT01992874 · 38 enrolled · United States
- Jul 3, 2025Day One Biopharmaceuticals's first study: phase 1 study in MelanomaNew to Day One BiopharmaceuticalsDay One Biopharmaceuticals · NCT07121829 · 44 enrolled · United States, Canada
TargetBeta
“An orally bioavailable small-molecule inhibitor of MEK1 and MEK2 (MEK1/2) ”NCIt, by rule
“Dual specificity mitogen-activated protein kinase kinase 1 inhibitor; Dual specificity mitogen-activated protein kinase kinase 2 inhibitor”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| cobimetinibrule | Hoffmann-La Roche | phase 3 | 38 |
| mirdametinibrule | Merck KGaA, Darmstadt, Germany | phase 2 | 9 |
| polfurmetinib | Pfizer | phase 1 | 3 |
Studies
All 13 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07121829Melanoma · United States, Canada | 1 | Terminated | Day One Biopharmaceuticals | Dec 18, 2024 | 44 |
| NCT01992874Neoplasms · United States | 1 | Completed | Merck KGaA, Darmstadt, Germany | May 31, 2014 | 38 |
| NCT01936363Ovarian Neoplasms · United States, Australia, Belgium and more | 2 | Completed | Merck KGaA, Darmstadt, Germany | May 31, 2015 | 65 |
| NCT01693068Melanoma · United States, Australia, Belgium and more | 2 | Completed | Merck KGaA, Darmstadt, Germany | Jul 4, 2015 | 194 |
| NCT01713036Neoplasms · Hungary | 1 | Completed | Merck KGaA, Darmstadt, Germany | Jul 31, 2014 | 6 |
| NCT01668017Carcinoma, Hepatocellular · Japan | 1 | Terminated | Merck KGaA, Darmstadt, Germany | May 31, 2015 | 26 |
| NCT01378377Neoplasms · United States | 1 | Terminated | Merck KGaA, Darmstadt, Germany | Feb 23, 2012 | 33 |
| NCT01357330Neoplasm Metastasis · United States | 1 | Completed | Sanofi | Jun 2012 | 18 |
| NCT01390818Neoplasm Metastasis · United States, Italy, Spain | 1 | Completed | Merck KGaA, Darmstadt, Germany | Apr 2015 | 146 |
| NCT01085331Colorectal Neoplasms · Belgium, Italy, Spain | 2 | Terminated | Merck KGaA, Darmstadt, Germany | Apr 2012 | 16 |
| NCT01016483Neoplasms · United States, Germany | 2 | Completed | Merck KGaA, Darmstadt, Germany | Dec 31, 2013 | 141 |
| NCT00982865Neoplasms · Australia, Belgium, France and more | 1 | Completed | Merck KGaA, Darmstadt, Germany | Mar 31, 2013 | 182 |
| NCT00957580Leukemia, Myeloid, Acute · United States, France | 2 | Terminated | Merck KGaA, Darmstadt, Germany | Dec 31, 2012 | 81 |
How it is read
Names in the registry
- “Pimasertib”, 16 entries
- “MSC1936369B”, 5 entries
- “Pimasertib Capsule (Part A)”, 2 entries
- “Pimasertib Tablet (Part A)”, 2 entries
- “MSC1936369B (pimasertib)”, 2 entries
Conditions, from the studies’ own filings
- Neoplasms, 5 studies
- Melanoma, 2 studies
- Neoplasm Metastasis, 2 studies
- Ovarian Neoplasms, 1 study
- Carcinoma, Hepatocellular, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.